Escitalopram Combination Comparison Study for Adult Patients With Major Depressive Disorder

Status unconfirmed · Phase 3

Conditions studied: Major Depressive Disorder

In brief

The purpose of this study is to evaluate the effectiveness, safety and tolerability of an escitalopram combination treatment compared to single treatments, and to placebo in patients with major depressive disorder.

Key facts

Study ID

NCT00239954

Run by

Pharmacology Research Institute

Starts

2005-03-01

Last updated by the study team

2012-05-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder
• The patient's current depressive episode must be at least 12 weeks in duration.

You may not qualify if…

• Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.
• Patients who currently meet DSM-IV criteria for : a. bipolar disorder; b. schizophrenia or any psychotic disorder; c. obsessive-compulsive disorder; d. mental retardation or any pervasive developmental disorder or cognitive disorder.
• Patients who are considered a suicide risk.
• Patients with a history of seizure disorder, or any history of seizure, stroke, significant head injury, or any other condition that predisposes toward risk of seizure.

Where it is running

• Pharmacology Research Institute — Los Alamitos, California, United States
• Pharmacology Research Institute — Newport Beach, California, United States
• Pharmacology Research Institute — Northridge, California, United States
• Pharmacology Research Institute — Riverside, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.